研究血清生物标志物在胰腺癌早期检测中的应用。
Examining the Use of Serum Biomarkers to Guide Early Detection of Pancreatic Cancer.
作者信息
Zhang Christina
机构信息
Christina Zhang.
出版信息
Clin J Oncol Nurs. 2025 Mar 14;29(2):151-156. doi: 10.1188/25.CJON.151-156.
BACKGROUND
Pancreatic cancer is estimated to become the second leading cause of cancer-related death by 2030 because of high malignancy, late diagnosis, inefficient therapy, and a lack of available screening for early detection.
OBJECTIVES
This article presents current clinical data supporting the use of serum biomarker signatures as a modality for early pancreatic ductal adenocarcinoma (PDAC) diagnosis and treatment.
METHODS
A clinical case study highlights the use of serum biomarker signatures in PDAC diagnosis. Clinical guidelines on PDAC were obtained from the National Comprehensive Cancer Network, the National Cancer Institute, StatPearls Publishing, the American Cancer Society, and the Pancreatic Cancer Detection Consortium.
FINDINGS
Screening barriers involve a low incidence and histologic heterogeneity of disease, as well as a need for prospective multicenter analysis of proposed biomarkers. Because the poor prognosis of PDAC is attributed to late detection, the development of a clinical guideline for biomarker-based screening warrants interprofessional awareness and advocacy in oncology clinical practice.
背景
由于胰腺癌恶性程度高、诊断晚、治疗效果不佳以及缺乏有效的早期检测筛查手段，预计到2030年，它将成为癌症相关死亡的第二大主要原因。
目的
本文介绍了当前支持使用血清生物标志物特征作为早期胰腺导管腺癌（PDAC）诊断和治疗方式的临床数据。
方法
一项临床病例研究突出了血清生物标志物特征在PDAC诊断中的应用。PDAC的临床指南来自美国国立综合癌症网络、美国国立癌症研究所、StatPearls出版社、美国癌症协会以及胰腺癌检测联盟。
研究结果
筛查障碍包括疾病发病率低和组织学异质性，以及对所提出的生物标志物进行前瞻性多中心分析的必要性。由于PDAC预后不良归因于检测延迟，基于生物标志物的筛查临床指南的制定需要肿瘤学临床实践中的跨专业认识和倡导。
Zotero 插件